News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • WPP's AI initiatives have moved beyond pilot stage toward commercial deployment.
  • WPP is converting client AI interest into billable work.
  • Technical indicators show improving patterns and a recovering share price.
  • The stock yields 3.4%, offering income for investors.
  • Trade view: tactical long with defined entry, stop and target over next 45 trading days.

Latest Articles

Waldencast plc Announces First Half 2026 Financial Results

Waldencast plc Announces First Half 2026 Financial Results

Waldencast plc announced its first half 2026 financial results, highlighting a 57.1% decrease in net revenue to $26.1 million from continuing operations largely due to the sale of its Obagi Medical business. The company recorded a net loss of $94.9 million from continuing operations, driven by declines in its Milk Makeup brand performance and a goo…

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Nyxoah Appoints Liam Kelly as Chief Executive Officer

Nyxoah SA announces the appointment of Liam Kelly as CEO to enhance its U.S. commercial presence following FDA approval and U.S. launch of its Genio system for treating Obstructive Sleep Apnea. Kelly brings over 25 years of industry leadership, primarily from U.S.-based MedTech firms. This leadership transition signals Nyxoah's commitment to scalin…

Exascale Labs Holdings Inc. Reports 111% Revenue Growth for Full Fiscal Year 2026 and Provides Business Update Following Successful Nasdaq Listing

Exascale Labs Holdings Inc. Reports 111% Revenue Growth for Full Fiscal Year 2026 and Provides Business Update Following Successful Nasdaq Listing

Exascale Labs Holdings Inc. announced a 111% revenue increase to $14.8 million for fiscal year 2026 driven by its GPU-as-a-Service platform. Following its successful Nasdaq listing under ticker XLAB, the company expanded strategic partnerships with Compal Electronics and EnergyBank to innovate next-gen GPU validation and offshore wind-powered AI co…

Rating Upgrade: SMCI Looks Like a Rare AI-Infrastructure Value Play

Rating Upgrade: SMCI Looks Like a Rare AI-Infrastructure Value Play

Super Micro Computer (SMCI) is benefitting from explosive AI data-center demand: fiscal 2026 revenue surged to $39.1B and management is guiding fiscal 2027 sales of $65-72B with AI solutions expected to exceed 80% of revenue. At a market cap near $27.5B and a forward P/E in the low-teens, the stock now offers a compelling risk-reward. This trade id…

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

SI-BONE, Inc. (Nasdaq: SIBN) received FDA 510(k) clearance for its iFuse Granite Onyx System, its first product targeting compromised bone outside the pelvis. This spinal fusion technology is designed specifically to reduce screw loosening at critical vertebrae in patients with poor bone quality, addressing an unmet clinical need that affects up to…

Applied Digital Sets Fiscal First Quarter 2027 Conference Call for Wednesday, October 7, 2026, at 5:00 p.m. Eastern Time

Applied Digital Sets Fiscal First Quarter 2027 Conference Call for Wednesday, October 7, 2026, at 5:00 p.m. Eastern Time

Applied Digital Corporation, a U.S.-based owner and operator of data centers tailored for high-performance computing and AI workloads, will host a conference call on October 7, 2026, to discuss fiscal Q1 2027 financial results. The company highlights its continued focus on HPC infrastructure, rapid deployment capabilities, and economic development …

AMD to Acquire World Labs to Advance the Future of AI Compute

AMD to Acquire World Labs to Advance the Future of AI Compute

AMD announced an $8.2 billion all-stock deal to acquire World Labs, an AI model and research lab led by Dr. Fei-Fei Li. The acquisition aims to enhance AMD's AI compute capabilities by integrating advanced AI model research into its hardware and software development, positioning AMD to better address emerging AI workloads and applications. Dr. Li w…

Adeia Appoints Dipti Vachani as Chief Executive Officer

Adeia Appoints Dipti Vachani as Chief Executive Officer

Adeia Inc. announced the appointment of Dipti Vachani as chief executive officer effective October 12, 2026. Vachani brings nearly 30 years of semiconductor industry experience with leadership roles at Arm, Intel, Skyworks, and Texas Instruments. She succeeds Paul Davis, who is stepping down for health reasons but will assist in transition. The new…

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026

Attovia Therapeutics announced presentations of new clinical and preclinical data for its ATTO-1310 and ATTO-2306 immunotherapies targeting IL-31 and IL-13 at the 2026 European Academy of Dermatology and Venereology Congress and Fall Clinical Dermatology Conference. Data includes Phase 1a safety results, translational insights on IL-31 in pruritic …

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Teva Pharmaceutical Industries received FDA approval for DEGEVMA™, a biosimilar to Amgen's Xgeva®, indicated for prevention of bone complications in adults with advanced cancer that has metastasized to the bone, treatment of giant cell tumor of bone, and hypercalcemia of malignancy. This approval complements the earlier FDA approval of PONLIMSI™, e…

Star Fashion Culture Holdings Limited  Announces Closing of Approximately US$9,600,000 Public Offering of Class A Ordinary Shares

Star Fashion Culture Holdings Limited Announces Closing of Approximately US$9,600,000 Public Offering of Class A Ordinary Shares

Star Fashion Culture Holdings Limited (NASDAQ: STFS) announced the closing of a best-efforts follow-on public offering of 12 million Class A ordinary shares at $0.80 per share, raising gross proceeds of approximately $9.6 million. The net proceeds will be used to develop the company's online marketing services and support general administration and…